Longitudinal analysis of head and neck cancer-specific immunity in patients treated with (salvage) surgery

Longitudinal analysis of head and neck cancer-specific immunity in patients treated with (salvage) surgery - Tumor-specific immunity in HNSCC treated with surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42765

Enrollment

Registered

2015-11-20

Start date

2016-04-18

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck cancer squamous cell carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: a. Histologically proven HPV positive or negative HNSCC with an indication for (salvage) surgery with/without adjuvant (C)RT in a curative setting b. Tumor site: oral cavity, and in case of salvage surgery: all sites c. Age above 18 years d. Performance score WHO 0,1 or 2 at time of study entry e. Written ICF

Exclusion criteria

Exclusion criteria: a. The use of immunosuppressive drugs at start of the treatment b. Anemia

Design outcomes

Primary

Measure	Time frame
a. To assess the presence and functionality of tumor-specific T cells as potential target for immunotherapy. b. To find potential predictive and/or prognostic markers in biopsied tumor material and peripheral blood. c. To study the kinetics of tumor-specific T cell populations in the tumor and blood over time, and the effect of treatment on that.	—

Countries

Netherlands

Outcome results